Clinical Progress in Neuroblastoma

References

• Brodeur GM, Castleberry RP. Neuroblastoma. Principles and Practice of Pediatric Oncology, 2nd ed, PA Pizzo, DG Poplack. JB Lippincott, Philadelphia 1992; 739–767
   Google Scholar
• Brodeur G, Seeger RC, Barrett A. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988; 6: 1874–1881
   PubMed Web of Science ®Google Scholar
• Breslow N, McCann B. Statistical estimation for prognosis for children with neuroblastoma. Cancer Res 1971; 31: 2098–2103
   PubMed Web of Science ®Google Scholar
• Silber JH, Evans AE, Fridman M. Models to predict outcome from childhood neuroblastoma: The role of serum ferritin and tumor histology. Cancer Res 1991; 51: 1426–1433
   PubMed Web of Science ®Google Scholar
• Rosen EM, Cassady JR, Frantz CN. Improved survival in neuroblastoma using multimodality therapy. Radiother Oncol 1984; 2: 189–200
   PubMed Web of Science ®Google Scholar
• Philip T. Overview of current treatment of neuroblastoma. Am J Pediatr Hematol/Oncol 1992; 14: 97–102
   PubMedGoogle Scholar
• Brodeur GM, Seeger RC, Schwab M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984; 224: 1121–1124
   PubMed Web of Science ®Google Scholar
• Seeger RC, Brodeur GM, Sather H. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313: 1111–1116
   PubMed Web of Science ®Google Scholar
• Nisen PD, Waber PG, Rich MA. N-myc oncogene RNA expression in neuroblastoma. J Natl Cancer Inst 1988; 80: 1633–1637
   PubMed Web of Science ®Google Scholar
• Fong CT, Dracopoli NC, White PS. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: Correlation with N-myc amplification. Proc Natl Acad Sci USA 1989; 86: 3753–3757
   PubMed Web of Science ®Google Scholar
• Look AT, Hayes FA, Shuster JJ. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma. A pediatric oncology group study. J Clin Oncol 1991; 9: 581–591
   PubMed Web of Science ®Google Scholar
• Hasse GM, Wong KY, DeLorimier AA. Improvement in survival after excision of primary tumor in stage III neuroblastoma. J Pediatr Surg 1989; 24: 194–200
   PubMed Web of Science ®Google Scholar
• Le Tourneau JN, Bernard JL, Hendren WH, Carcassonne M. Evaluation of the role of surgery in 130 patients with neuroblastoma. J Pediatr Surg 1985; 20: 244–249
   PubMed Web of Science ®Google Scholar
• Matsumura M, Atkinson JB, Hays DM. An evaluation of the role of surgery in metastatic neuroblastoma. J Pediatr Surg 1988; 23: 448–453
   PubMed Web of Science ®Google Scholar
• Cheung NK, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 1991; 9: 1050–1058
   PubMed Web of Science ®Google Scholar
• Phillip T, Zucker JM, Bernard JL. Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: Is cure possible in a small subgroup. J Clin Oncol 1991; 9: 1037–1044
   PubMed Web of Science ®Google Scholar
• Graham-Pole J, Casper J, Elfenbein G. High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 1991; 9: 152–158
   PubMed Web of Science ®Google Scholar
• Seeger RC, Villablanca JG, Matthay KK. Intensive chemoradiotherapy and autologous bone marrow transplantation for poor prognosis neuroblastoma. Prog. Clin. Biol. Res, vol 366: Advances in Neuroblastoma Research 3, AE Evans, GJ D'Angio, AG Knudson, RC Seeger. Wiley Liss, New York 1991; 527–534
   Google Scholar
• Chan HS, Haddad G, Thorner PS. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991; 325: 1608–1614
   PubMed Web of Science ®Google Scholar
• Hayes FA, Green AA, Rao B. Clinical manifestations of ganglioneuroma. Cancer 1989; 63: 1211–1214
   PubMed Web of Science ®Google Scholar
• Brodeur G, Pritchard J, Berthold F. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 1993; 11: 1466–1477
   PubMed Web of Science ®Google Scholar
• Daubenton J, Fisher R, Karabus C. The relationship between prognosis and scintigraphic evidence of bone metastase in neuroblastoma. Cancer 1987; 59: 1586–1589
   PubMed Web of Science ®Google Scholar
• Kaufman RA, Thrall JH, Keyes JW. False negative bone scans in neuroblastoma metastatic to the ends of long bones. Am J R 1978; 130: 131–135
   PubMed Web of Science ®Google Scholar
• Yeh SD, Larson SM, Burch L. Radioimmunodetection of neuroblastoma with iodine-131-3F8: Correlation with biopsy, iodine-131-metaiodobenzylguanidine (MIBG) and standard diagnostic modalities. J Nucl Med 1991; 32: 769–776
   PubMed Web of Science ®Google Scholar
• Gordon I, Peters AM, Gulman A. Skeletal assessment in neuroblastoma—The pitfalls of iodine-123-MIBG scans. J Nucl Med 1990; 31: 129–134
   PubMed Web of Science ®Google Scholar
• Schmiegelow K, Siimes MA, Agertoft L. Radioiodobenzylguanidine scintigraphy of neuroblastoma: Conflicting results, when compared with standard investigation. Med Pediatr Oncol 1989; 17: 126–130
   Google Scholar
• Caballero O, Ferris J, Verdeguer A. Visualization of a ganglioneuroma by means of scintigraphy with 131-I-MIBG. Eur J Nucl Med 1986; 12: 351–352
   PubMedGoogle Scholar
• Garty I, Freidman A, Sandler M. Neuroblastoma: imaging evaluation by sequential Tc-99m MDP, 1–131 Mibg, and Ga-67 Citrate Studies. Clin Nucl Med 1989; 14: 515–522
   PubMed Web of Science ®Google Scholar
• Hann H-WL, Evans AE, Siegel SE. Prognostic importance of serum ferritin in patients with stages III and IV neuroblastoma: The Children's Cancer Study Group Experience. Cancer Res 1985; 45: 2843–2848
   PubMed Web of Science ®Google Scholar
• Berthold F, Trechow R, Utsch S. Prognostic factors in metastatic neuroblastomas. A multivariate analysis of 182 cases. Am J Pediatr Hematol/Oncol 1992; 14: 207–215
   PubMedGoogle Scholar
• De Bernardi B, Pianca C, Boni L. Disseminated neuroblastoma (stage IV and IV-S) in the first year of life. Cancer 1992; 70: 1625–1633
   PubMed Web of Science ®Google Scholar
• Zeltzer PM, Marangos PJ, Evans AE, Schneider SL. Serum neuron-specific enolase in children with neuroblastoma. Relationship to stage and disease course. Cancer 1986; 57: 1230–1234
   PubMed Web of Science ®Google Scholar
• Valentino L, Moss Olson T.E. Shed tumor gangliosides and progression of human neuroblastoma. Blood 1990; 75: 1564–1567
   PubMed Web of Science ®Google Scholar
• Wu Z, Schwartz E, Seeger RC, Ladisch S. Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res 1986; 46: 440–443
   PubMed Web of Science ®Google Scholar
• Ladisch S, Wu Z-L, Feig S. Shedding of GD2 ganglioside by human neuroblastoma. Int J Cancer 1987; 39: 73–76
   PubMed Web of Science ®Google Scholar
• Ladisch S, Kitada S, Hays EF. Gangliosides shed by tumor cells enhance tumor formation in mice. J Clin Invest 1987; 79: 1879–1882
   PubMed Web of Science ®Google Scholar
• Weinkove C. Measurement of catecholamines and their metabolites in urine. Clinical pathology 1991; 44: 269–275
   PubMed Web of Science ®Google Scholar
• Laug WE, Siegel SE, Shaw K NF. Initial urinary catecholamine metabolite concentrations and prognosis in neuroblastoma. Pediatrics 1978; 62: 77–83
   PubMed Web of Science ®Google Scholar
• Evans AE, D'Angio GJ, Sather HN. A comparison of four staging systems for localized and regional neuroblastoma: A report from the Children's Cancer Study Group. J Clin Oncol 1990; 8: 678–688
   PubMed Web of Science ®Google Scholar
• Shimada H, Chatten J, Newton WA, Jr. Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classificaiton of neuroblastomas. J Natl Cancer Inst 1984; 73: 405–416
   PubMed Web of Science ®Google Scholar
• Shimada H. Neuroblastoma. Pathology and biology. Acta Pathol Jpn 1992; 42: 229–241
   PubMedGoogle Scholar
• Joshi V, Chatten J, Sather H. Evaluation of the Shimada classification in advanced neuroblastoma with a special reference to the mitosis-karryorrhexis index: A report from the Children's Cancer Study Group. Modern pathology 1991; 4(2)139–147
   PubMed Web of Science ®Google Scholar
• Joshi VV, Cantor AB, Altshuler G. Recommendations for modification of terminology of neuroblastic tumors and prognostic significance of Shimada classification. Cancer 1992; 69: 2183–2196
   PubMed Web of Science ®Google Scholar
• Joshi VV, Cantor AB, Altshuler G. Age-linked prognostic categorization based on a new histologic grading system of neuroblastomas. Cancer 1992; 69: 2197–2211
   PubMed Web of Science ®Google Scholar
• Kushner BH, LaQuaglia MP, Bonilla MA. Aggressive multi-modality induction therapy of stage IV neuroblastoma (NB) in children over one year of age: Preliminary results. Proc Am Soc Clin Oncol 1992; 11: 367
   Google Scholar
• O'Leary M, Sather H, Ramsay N KC. Intensive chemotherapy for stage IV neuroblastoma (NB) over one year of age. Proc Am Soc Clin Oncol 1989; 8: 307, (abstract)
   Google Scholar
• Shafford EA, Rogers DW, Pritchard J. Advanced neuroblastoma: Improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM26. J Clin Oncol 1984; 2: 742–747
   PubMed Web of Science ®Google Scholar
• Goldie JH, Coldman AJ. The somatic mutation theory of drug resistance: The “Goldie-Coldman” hypothesis revisited. Cancer. Principles and Practice of Oncology, 3rd ed., HR Devita. JP Lippincott, Philadelphia 1989; Vol. 3: 1–12
   Google Scholar
• Kushner BH, Sullivan M, Cheung N KV. Intensive dosing and dose rate using cyclophosphamide (CTX) in ablation of neuroblastoma (NB): Preliminary results. Proc Am Assoc Cancer Res 1989; 30: 279
   Google Scholar
• Haase G, O'Leary M, Ramsay N. Aggressive surgery combined with intensive chemotherapy improves'survival in poorrisk neuroblastoma. J Pediatr Surg 1991; 26(9)1119–1124
   PubMed Web of Science ®Google Scholar
• Seeger R, Reynolds C. Treatment of high-risk solid tumors of childhood with intensive therapy and autologus bone marrow transplantation. Pediatr Clin North Am 1991; 38: 393–424
   PubMed Web of Science ®Google Scholar
• Dini G, Lanino E, Garaventa A. Myeloblative therapy and unpurged autologous bone marrow transplantation for poorprognosis neuroblastoma: Report of 34 cases. J Clin Oncol 1991; 9: 962–969
   PubMedGoogle Scholar
• Shuster JJ, Cantor AB, McWilliams N. The prognostic significance of autologous bone marrow transplant in advanced neuroblastoma. J Clin Oncol 1991; 9: 1045–1049
   PubMed Web of Science ®Google Scholar
• Kushner BH, O'Reilly RJ, Mandell LR. Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. J Clin Oncol 1991; 9: 274–279
   PubMed Web of Science ®Google Scholar
• Brandt S, Peters W, Atwater S. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on he matopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988; 318: 869–876
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Singer J, Buckner C. Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous marrow transplantation for lymphoid malignancies. Blood 1988; 72: 834–836
   PubMed Web of Science ®Google Scholar
• Moss TJ, Reynolds P, Sather HN. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med 1991; 324: 219–226
   PubMed Web of Science ®Google Scholar
• Combaret V, Favrot M, Kremens C.B. Immunological detection of neuroblastoma cells in bone marrow harvested for autologous transplantation. Br J Cancer 1989; 59: 844–847
   PubMed Web of Science ®Google Scholar
• Rowley SD, Zuehlsdorf M., Braine HG. CFU-GM content of bone marrow graft correlates with time to hematologic reconstitution following autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide-purged bone marrow. Blood 1987; 70: 271–275
   PubMed Web of Science ®Google Scholar
• Treleaven JG, Ugelstad J, Philip T. Removal of neuroblastoma cells from bone marrow with monoclonal antibodies conjugated to magnetic microspheres. Lancet 1984; 1: 70–73
   PubMed Web of Science ®Google Scholar
• Reynolds C, Vo D, Seeger RC. Model system for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads. Cancer Res 1986; 46: 5882–5886
   PubMed Web of Science ®Google Scholar
• Berenson R, Bensinger Hill W.R. Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood 1991; 77: 1717–1722
   PubMed Web of Science ®Google Scholar
• Lasky L, Bostrom B, Smith J. Clinical collection and use of peripheral blood stem cells in pediatric patients. Transplantation 1989; 47: 613–616
   PubMed Web of Science ®Google Scholar
• Moss TJ, Sanders DG, Lasky LC, Bostrom B. Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells. Blood 1990; 76: 1879–1883
   PubMed Web of Science ®Google Scholar
• Mattano LA, Moss TJ, Emerson SG. Sensitive Detection of rare circulating neuroblastoma cells by the reverse transcriptasepolymerase chain reaction. Cancer Res 1992; 52: 4701–4705
   PubMed Web of Science ®Google Scholar
• Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986; 70: 163–169
   PubMedGoogle Scholar
• Cheung NK. Biological and molecular approaches to treatment. Immunotherapy. Principles and Practice of Pediatric Oncology, 2nd ed., PA Pizzo, DG Poplack. JB Lippincott, Philadelphia 1992; 357–370
   Google Scholar
• Rosenberg S, Lotze M, Muul L. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316: 889–897
   PubMed Web of Science ®Google Scholar
• Negrier S, Michon J, Floret D. Interleukin-2 and lymphokine-activated killer cells in 15 children with advanced metastatic neuroblastoma. J Clin Oncol 1991; 9: 1363–1370
   PubMed Web of Science ®Google Scholar
• Evans AE, Main E, Zier K. The effects of gamma interferon on natural killer and tumor cells of children with neuroblastoma. A preliminary report. Cancer 1989; 64: 1383–1387
   PubMed Web of Science ®Google Scholar
• Smith MA, Parkinson DR, Cheson BD, Friedman MA. Retinoids in cancer therapy. J Clin Oncol 1992; 10: 839–864
   PubMed Web of Science ®Google Scholar
• Thiele CJ, Reynolds CP, Israel MA. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 1985; 313: 404–406
   PubMed Web of Science ®Google Scholar
• Wuarin Verity L.M., Sidell N. Effects of interferon gamma and its interaction with retinoic acid on human neuroblastoma differentiation. Int J Cancer 1991; 48: 136–141
   PubMed Web of Science ®Google Scholar
• Mastrangelo R, Troncone L, Lasorella A. 131-1-metaiodobenzylguanidine in the treatment of neuroblastoma at diagnosis. Pediatr Hematol Oncol 1989; 11: 28–31
   Web of Science ®Google Scholar
• Voute PA, Hoefnagel CA, De Kraker J. Results of treatment with 131-I-metaiodobenzylguanidine in patients with neuroblastoma. Future prospects of zetotherapy. Prog. Clin. Biol. Res, 336: Advances in Neuroblastoma Research 3, AE Evans, DJ D'Angio, AG Knudson, RC Seeger. Wiley-Liss, New York 1991; 439–445
   Google Scholar
• Moyes JS, Babich JW, Carter R. Quantitative study of radioiodinated metaiodobenzylguanidine uptake in children with neuroblastoma: correlation with tumor histopathology. J Nucl Med 1989; 30: 474–480
   PubMed Web of Science ®Google Scholar
• Lewis IJ, Lashfor LS, Fielding S. A phase I/II study of 131 I-MIBG in chemoresistant neuroblastoma. Prog. Clin. Biol. Res, 366: Advances in Neuroblastoma Research 3, AE Evans, DJ D'Angio, AG Knudson, RC Seeger. Wiley-Liss, New York 1991; 463–469
   Google Scholar
• Baum RP, Maul FD, Schwarz A. Diangosis and treatment of stage IV neuroblastoma with Tc-99mm and I-131 labeled monoclonal antibody BW 575/9. J Nucl Med 1989; 30: 904
   Google Scholar
• Cheung NK, Yeh S DJ, Gulati S. 131I-3F8 targeted radiotherapy of neuroblastoma (NB): A phase I clinical trial. Proc Am Assoc Cancer Res 1990; 31: 284
   Google Scholar
• Rodwell JD. Engineering monoclonal antibodies. Nature 1989; 342: 99–100
   PubMed Web of Science ®Google Scholar
• McMurry TJ, Brechbiel M, Kumar K, Gansow OA. Convenient synthesis of bifunctional tetraazamacrocycles. Bioconjug Chem 1992; 3: 108–117
   PubMed Web of Science ®Google Scholar
• Waldmann TA. Monoclonal antibodies in diagnosis and therapy. Science 1991; 252: 1657–1662
   PubMed Web of Science ®Google Scholar
• Goodman SN. Neuroblastoma screening data. An epidemiologic analysis. Am J Dis Child 1991; 145: 1415–1422
   PubMedGoogle Scholar
• Nakagawara A, Arima M., Azar CO. Inverse relationship between trk and N-myc amplification in human neuroblastoma. Cancer Res 1992; 52: 1364–1368
   PubMed Web of Science ®Google Scholar
• Nakagawara N, Nakagawara A, Scavarda NJ. High expression of the TRK gene in human neuroblastoma is associated with favorable outcome: Possible role in tumor differentiation and regression. N Engl J Med 1993
   PubMed Web of Science ®Google Scholar
• Grant SC, Gralla RJ, Kris MG. Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: The case for studies in previously treated patients. J Clin Oncol 1992; 10: 484–496
   PubMed Web of Science ®Google Scholar
• Eckardt JR, Burris HA, Rothenberg ML. Topoisomerase I inhibitors: Promising novel compounds. Contemp Oncol January, 1993; 47–60
   Google Scholar
• Culver KW, Ram Z, Wallbridge S. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550–1552
   PubMed Web of Science ®Google Scholar
• Ezzeddine ZD, Martuza RL, Platika D. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol 1991; 3: 608–614
   PubMedGoogle Scholar
• Moss B. Vaccinia virus: A tool for research and vaccine development. Science 1991; 252: 1662–1667
   PubMed Web of Science ®Google Scholar